1. What's New in PAH?

3. Introduction Recent Events and Publications in PAH

4. Updates to Hemodynamic Definitions: PH

5. Updated Clinical Classification of Group 1:PAH

6. Group 1.3: Drug-and Toxin-Induced PAH

7. Group 1.5: PAH Long-Term Responders to Calcium Channel Blockers

8. Group 1.6: PAH With Overt Features of Venous/Capillaries (PVOD/PCH) Involvement

9. REVEAL Risk Score 2.0

10. REVEAL Risk Score 2.0 What Has Changed?

11. ESC/ERS Risk Assessment Categories for PAH

12. Risk Scores and Survival Analyses Based on REVEAL 2.0

13. Risk Scores Across Registries Based on REVEAL Update to 2.0

14. Registration Studies for Current PAH Therapies Study Duration and Primary Outcome Measure

15. Treatment Strategy and Evolution of Combination Therapy

16. Pharmacologic Agents for PAH Multiple Pathways

17. Treatment Algorithm for PAH Treatment-Naive

18. Treatment Algorithm for PAH Patient Already on Treatment

19. Reassessing and Modifying Treatment

20. Clinical Considerations: Does PAH Therapy Need Modification or Escalation?

21. Continual Re-Assessment of Risk Status

22. Implementation Strategies

23. Concluding Remarks

24. Abbreviations

25. Abbreviations (cont)

26. Abbreviations (cont)